# US 2026/0199455 A1 · Erap1 modulating compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0199455 A1
- Document ID: US20260199455A1
- Status: Published application
- Kind: A1
- Application number: 19/265,665
- Filed: 2025-07-10
- Published: 2026-07-16
- Earliest claimed: 2018-11-23
- Assignees: Grey Wolf Therapeutics Limited
- Applicants: Grey Wolf Therapeutics Limited
- Inventors: Martin Quibell; Anil Lallubhai Patel; Jason John Shiers; Michael Sparenberg; Peter Ian Joyce
- Web page: https://patentgrep.com/patent/US20260199455A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- C07D 295/12: substituted by singly or doubly bound nitrogen atoms (nitro radicals C07D295/06)
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/402: 1-aryl substituted, e.g. piretanide
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/497: containing further heterocyclic rings
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 207/12: Oxygen or sulfur atoms
- C07D 209/44: Iso-indoles; Hydrogenated iso-indoles
- C07D 211/10: with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D 211/14: with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C07D 211/38: Halogen atoms or nitro radicals
- C07D 211/42: attached in position 3 or 5
- C07D 211/44: attached in position 4
- C07D 211/46: having a hydrogen atom as the second substituent in position 4
- C07D 211/48: having an acyclic carbon atom attached in position 4
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 257/04: Five-membered rings
- C07D 295/135: with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 295/185: from aliphatic carboxylic acids
- C07D 305/06: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/08: Bridged systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 493/08: Bridged systems
- C07D 493/10: Spiro-condensed systems
- C07D 498/08: Bridged systems
- A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure relates to a compound of formula (Ia), or a pharmaceutically acceptable salt or hydrate thereof, The present disclosure further relates to pharmaceutical compositions comprising a compound of formula (Ia) and methods of treating a disease or disorder (e.g., cancer) by administering a compound of formula (Ia).

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A method of treating or preventing a disorder selected from the group consisting of a proliferative disorder, an immune disorder, a viral disorder, and an inflammatory disorder in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of a compound of formula (Id), or a pharmaceutically acceptable salt or hydrate thereof,
wherein:
the group X—Y is —NHSO2— or —SO2NH—;
R1 is H or alkyl;
R2 is selected from COOH and a tetrazolyl group;
R3 is selected from H, Cl and alkyl;
R4 is selected from H, Cl and F;
R5 is selected from H, alkyl, alkenyl, alkynyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy;
R6 is H;
R7 is CN, SO2-alkyl, SO2NR13R14 or a heteroaryl group, wherein said heteroaryl group is optionally substituted by one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH;
R8 is selected from H, alkyl, haloalkyl and halo;
R9 is H, C1-C3-alkyl or halo;
R10 is H or alkyl;
R11 is alkyl optionally substituted by one or more substituents selected from NH2, OH, and NHCO2R12, wherein R12 is alkyl; or
R10 and R11, together with the nitrogen to which they are attached, form a 4, 5, 6 or 7-membered monocyclic heterocycloalkyl group, wherein one or two carbons in the monocyclic heterocycloalkyl group are optionally replaced by a group selected from O, NH, S and CO, and said monocyclic heterocycloalkyl group is optionally substituted by one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, wherein said heteroaryl group is in turn optionally further substituted with one or more groups selected from halo and alkyl; or
R10 and R11, together with the nitrogen to which they are attached, form an 8, 9 or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced by a group selected from O, NH, S and CO, and said bicyclic heterocycloalkyl group is optionally substituted by one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl; or
R10 and R11, together with the nitrogen to which they are attached, form a 6 to 12-membered bicyclic group containing a spirocyclic carbon atom, wherein one or two carbons in the bicyclic group are optionally replaced by a group selected from O, NH, S and CO, and said bicyclic group is optionally substituted by one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, or said bicyclic group is optionally fused to a 5 or 6-membered aryl or heteroaryl group; and
R13 and R14 are each independently H or alkyl.

### Claim 21 (depends on 20)

The method according to claim 20, wherein R10 and R11, together with the nitrogen to which they are attached, form a 6-membered monocyclic heterocycloalkyl group, wherein one or two carbons in the monocyclic heterocycloalkyl group are optionally replaced by a group selected from O, NH, S and CO, and said monocyclic heterocycloalkyl group is optionally substituted by one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, wherein said heteroaryl group is in turn optionally further substituted with one or more groups selected from halo and alkyl.

### Claim 22 (depends on 20)

The method according to claim 20, wherein R7 is a heteroaryl group selected from imidazolyl, pyrazolyl, pyrazinyl, pyradizinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, tetrazolyl and triazolyl, each of which is optionally substituted by one or more substituents selected from alkyl, halo, alkoxy, ON, haloalkyl and OH.

### Claim 23 (depends on 20)

The method according to claim 20, wherein R7 is a heteroaryl group selected from 1H-pyrazol-5-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, oxazol-2-yl, 1H-1,2,3-triazol-4-yl, 1H-1,2,3-triazol-5-yl, thiazol-5-yl, 1H-1,2,3,4-tetrazol-4-yl, 2H-1,2,3,4-tetrazol-5-yl, isoxazol-4-yl, isoxazol-5-yl, isothiazol-5-yl, pyradizin-3-yl, pyradizin-4-yl, pyrazinyl and 1,3,4-oxadizol-2-yl, each of which is optionally substituted by one or more substituents selected from Me, F, Cl, ON and MeO.

### Claim 24 (depends on 20)

The method according to claim 20, wherein the compound of formula (Id) is selected from the group consisting of:
and pharmaceutically acceptable salts and hydrates thereof.

### Claim at position 7

25-33. (canceled)

### Claim 34 (depends on 20)

The method according to claim 20, wherein the disorder is a proliferative disorder.

### Claim 35

(canceled)

### Claim 36 (depends on 34)

The method according to claim 34, wherein the proliferative disorder is cancer.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the compound of formula (Id) stimulates a neo-antigen directed immune response in the subject, and wherein the method further comprises the subsequent administration of a second compound to stimulate the same neo-antigen as the compound of formula (Id).

### Claim 38 (depends on 36)

The method according to claim 36, wherein the subject has previously had cancer, has a familial history of cancer, has a high risk for developing cancer, has a genetic predisposition to developing cancer, has been exposed to a carcinogenic agent, and/or is in remission from cancer.

### Claim 39

An in vitro or in vivo method for producing an antigen-presenting cell which presents a neo-antigen, said method comprising inducing with a compound of formula (Id):
or a pharmaceutically acceptable salt or hydrate thereof a neo-antigen in said antigen-presenting cell, wherein:
the group X—Y is —NHSO2— or —SO2NH—;
R1 is H or alkyl;
R2 is selected from COOH and a tetrazolyl group;
R3 is selected from H, Cl and alkyl;
R4 is selected from H, Cl and F;
R5 is selected from H, alkyl, alkenyl, alkynyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy;
R6 is H;
R7 is CN, SO2-alkyl, SO2NR13R14 or a heteroaryl group, wherein said heteroaryl group is optionally substituted by one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH;
R8 is selected from H, alkyl, haloalkyl and halo;
R9 is H, C1-C3-alkyl or halo;
R10 is H or alkyl;
R11 is alkyl optionally substituted by one or more substituents selected from NH2, OH, and NHCO2R12, wherein R12 is alkyl; or
R10 and R11, together with the nitrogen to which they are attached, form a 4, 5, 6 or 7-membered monocyclic heterocycloalkyl group, wherein one or two carbons in the monocyclic heterocycloalkyl group are optionally replaced by a group selected from O, NH, S and CO, and said monocyclic heterocycloalkyl group is optionally substituted by one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, wherein said heteroaryl group is in turn optionally further substituted with one or more groups selected from halo and alkyl; or
R10 and R11, together with the nitrogen to which they are attached, form an 8, 9 or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced by a group selected from O, NH, S and CO, and said bicyclic heterocycloalkyl group is optionally substituted by one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl; or
R10 and R11, together with the nitrogen to which they are attached, form a 6 to 12-membered bicyclic group containing a spirocyclic carbon atom, wherein one or two carbons in the bicyclic group are optionally replaced by a group selected from O, NH, S and CO, and said bicyclic group is optionally substituted by one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, or said bicyclic group is optionally fused to a 5 or 6-membered aryl or heteroaryl group; and
R13 and R14 are each independently H or alkyl.

### Claim 40 (depends on 39)

An immunogenic composition comprising an antigen-presenting cell obtained or obtainable by the method according to claim 39.

### Claim 41 (depends on 40)

A method for treating or preventing cancer in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to claim 40.

### Claim 42 (depends on 34)

The method according to claim 34, wherein said compound is used in combination with an immunotherapy.

### Claim 43 (depends on 42)

The method according to claim 42, wherein said immunotherapy is an immune checkpoint intervention.

### Claim 44 (depends on 43)

The method according to claim 43, wherein said immune checkpoint intervention is an antibody checkpoint inhibitor selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-CTLA4 antibody.

### Claim 45 (depends on 20)

The method according to claim 20, wherein the disorder is an immune disorder.

### Claim 46 (depends on 20)

The method according to claim 20, wherein the disorder is an inflammatory disorder.

### Claim 47 (depends on 20)

The method according to claim 20, wherein the viral disorder is an infectious viral disease selected from the group consisting of HIV, HPV, CMV, and HCV.

### Claim 48 (depends on 20)

The method according to claim 20, wherein the disorder is cancer, and wherein the compound increases the visibility of cancer cells to the immune system by altering the repertoire of antigens and neoantigens presented to the immune system.

### Claim 49 (depends on 48)

The method according to claim 48, wherein the compound increases the CD8+ T cell response to the cancer cell.

### Claim 50

A method of treating or preventing a disorder selected from the group consisting of a proliferative disorder, an immune disorder, a viral disorder, and an inflammatory disorder in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof,
wherein:
the group X—Y is —NHSO2— or —SO2NH—;
R1 is H or alkyl;
R2 is selected from COOH and a tetrazolyl group;
R3 is selected from H, Cl and alkyl;
R4 is selected from H, Cl and F;
R5 is selected from H, alkyl, alkynyl, alkenyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy;
R6 is H;
R7 is selected from H, CN, haloalkyl, Cl, F, SO2-alkyl, SO2NR13R14, heteroaryl and alkyl, wherein said heteroaryl group is optionally substituted by one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH;
R8 is selected from H, alkyl, haloalkyl and halo;
R9 is H, C1-C3-alkyl or halo;
R10 is H or alkyl;
R11 is alkyl optionally substituted by one or more substituents selected from NH2, OH, and NHCO2R12, wherein R12 is alkyl; or
R10 and R11, together with the nitrogen to which they are attached, form a 4, 5, 6 or 7-membered monocyclic heterocycloalkyl group, wherein one or two carbons in the monocyclic heterocycloalkyl group are optionally replaced by a group selected from O, NH, S and CO, and said monocyclic heterocycloalkyl group is optionally substituted by one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, wherein said heteroaryl group is in turn optionally further substituted with one or more groups selected from halo and alkyl; or
R10 and R11, together with the nitrogen to which they are attached, form an 8, 9 or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced by a group selected from O, NH, S and CO, and said bicyclic heterocycloalkyl group is optionally substituted by one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl; or
R10 and R11, together with the nitrogen to which they are attached, form a 6 to 12-membered bicyclic group containing a spirocyclic carbon atom, wherein one or two carbons in the bicyclic group are optionally replaced by a group selected from O, NH, S and CO, and said bicyclic group is optionally substituted by one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, or said bicyclic group is optionally fused to a 5 or 6-membered aryl or heteroaryl group; and
R13 and R14 are each independently H or alkyl.

### Claim 51 (depends on 50)

The method according to claim 50, wherein the compound is selected from the following:
and pharmaceutically acceptable salts and hydrates thereof.

### Claim at position 26

52-69. (canceled)

### Claim 70 (depends on 20)

The method of claim 20, wherein R10 and R11, together with the nitrogen to which they are attached, form a piperidinyl group which is optionally substituted by one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, wherein said heteroaryl group is in turn optionally further substituted with one or more groups selected from halo and alkyl.

### Claim 71 (depends on 20)

The method of claim 20, wherein R10 and R11, together with the nitrogen to which they are attached, form an unsubstituted piperidinyl group.

### Claim 72 (depends on 20)

The method of claim 20, wherein R8 is selected from H, Me, CF3, Cl, Br, and F.

### Claim 73 (depends on 20)

The method of claim 20, wherein R2 is COOH.

### Claim 74 (depends on 20)

The method of claim 20, wherein R7 is CN.
